QOL and outcomes research in prostate cancer patients with low socioeconomic status

被引:0
作者
Kim, SP
Benett, CL
Chan, C
Chmiel, J
Falcone, D
Knight, SJ
Kuzel, T
Davis, TC
Elstein, AS
Moran, E
Robertson, CN
Smith, JS
机构
[1] Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA
[2] VA Chicago Hlth Care Syst, Lakeside Div, Chicago, IL USA
[3] Louisiana State Univ, Med Ctr, Shreveport, LA USA
[4] Univ Illinois, Coll Med, Chicago, IL USA
[5] Long Beach VA Reg Med Ctr, Long Beach, CA USA
[6] Duke Univ, Med Ctr, Durham, NC USA
来源
ONCOLOGY-NEW YORK | 1999年 / 13卷 / 06期
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The VA Cancer of the Prostate Outcomes Study (VA CaPOS) is collecting quality-of-life (QOL) information from prostate cancer patients, spouses, and physicians at six VA medical centers. Currently, 601 men with prostate cancer are included in the study, most of whom ave of low socioeconomic status and over half of whom are African-American. Quality-of-life responses were most favorable for newly diagnosed patients, intermediate for those with stable metastatic disease, and poorest for those with progressive metastatic disease. Patients could not provide reliable estimates of their own preferences for future QOL states but responded reliably to questions phrased as a comparison of the preferences of two hypothetical patients. High out-of-pocket costs for hormonal therapies, lack of health insurance, and a belief that the non-VA system offered poorer services were the most common reasons for patient transferral to the VA system. Satisfaction with medical care was generally high. While African-American patients were more likely to have advanced prostate cancer at diagnosis, after adjustment for differences in health literacy, race was no longer a significant predictor of advanced disease, The VA CaPOS provides useful information on health statics and patient satisfaction of VA prostate cancer patients. Long-term evaluations are needed to detect clinically meaningful QOL information as the disease progresses.
引用
收藏
页码:823 / 832
页数:10
相关论文
共 29 条
[1]  
AARONSON NK, 1990, J INTERN MED, V5, P29
[2]  
ALBERTSEN PC, 1997, UROLOGY, V50, P920
[3]  
Bennett CL, 1997, EUR UROL, V32, P86
[4]  
CASSILETH BR, 1992, QUAL LIFE RES, V1, P232
[5]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[6]   Prostate cancer patients' utilities for health states: How it looks depends on where you stand [J].
Chapman, GB ;
Elstein, AS ;
Kuzel, TM ;
Sharifi, R ;
Nadler, RB ;
Andrews, A ;
Bennett, CL .
MEDICAL DECISION MAKING, 1998, 18 (03) :278-286
[7]  
DASILVA FC, 1993, CANCER S, V1, P1133
[8]  
DAVIES AR, 1986, HEALTH SERV RES, V21, P429
[9]  
Davis T C, 1993, Fam Med, V25, P391
[10]  
EPSER P, 1997, UROLOGY, V50, P920